Florida Cancer Specialists & Research Institute (FCS) is seeking to reduce deaths and suffering from hereditary cancers with the launch of a cancer genetics program across its statewide practice. The use of a powerful and proven technology tool developed by Chicago-based software and data analytics company, CancerIQ, and the addition of a specially-trained genetic professional will help identify patients whose cancer is linked to genetics and those at increased likelihood of developing cancer. The partnership between FCS and CancerIQ is the first of its kind within community oncology and will roll out within the practices in phases, beginning in early August.

“Hereditary cancers are often aggressive and tend to affect younger people,” notes FCS President & Managing Physician Dr. Lucio Gordan. Women and men can inherit genetic mutations from their parents that put them at increased risk of developing certain cancers, such as melanoma, breast, colon and prostate cancer, among others. “This powerful new screening tool will enable us to compile a comprehensive health history for patients and understand what factors might play a role in developing other types of cancers.”

“Knowing risk factors for hereditary cancers early can be life-saving, allowing patients to take preventive measures that can preempt or prevent the disease,” said FCS Chief Operating Officer Todd Schonherz. “Supported by this technology, we are able to identify and refer eligible candidates for a high-risk consultation and ensure they get the timely preventive services they need to reduce their risk.”

Using an iPad or other handheld mobile device, patients answer simple multiple-choice questions. CancerIQ then analyzes family history and runs predictive risk models. Those flagged as high risk are referred for genetic counseling, testing, and personalized care management. The technology assists in the development of a comprehensive care plan based on national clinical guidelines from the National Comprehensive Cancer Network.

Click here for more info.